Estefania Gauto Mariotti

Estefania Gauto Mariotti

Auto-generated profile, based on publicly available information

Estefania Gauto Mariotti

Division of Hematology Mayo Clinic Rochester Minnesota USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2025 in Cells
Verified
Journal Article
Open access
PDF file
BMBenjamin Massat
Benjamin Massat
PSPatrick Stiff
Patrick Stiff
FEFatema Esmail
Fatema Esmail
EGEstefania Gauto-Mariotti
Estefania Gauto-Mariotti
PHPatrick A Hagen
Patrick A Hagen
Despite the increasing number of novel therapies to treat newly diagnosed multiple myeloma (NDMM), preventing skeletal-related events (SREs) remains a challenge. This review summarizes the mechanistic causes of myeloma bone disease, data supporting the use of bisphosphonates and RANKL inhibitors, and the optimal management of preventing SREs in NDMM patients. Both zoledronic acid (ZA) and denosumab are acceptable treatment options with comparable safety and efficacy profiles. However, in patients who are candidates for autologous stem cell transplant (ASCT), denosumab may be preferred over ZA due to a progression-free survival (PFS) benefit observed in post hoc analyses when used with proteasome inhibitor-based regimens. The optimal duration of bone-directed therapy is unclear, but it is typically given for two years. Supportive care should include dental evaluation at baseline, annually, and if symptoms appear, given the risk for jaw osteonecrosis with both ZA and denosumab. Both drugs should be held in the setting of dental work. Patients should receive adequate calcium and vitamin D supplementation. Supportive procedures such as cement augmentation, radiation, and orthopedic surgery can also help treat compression fractures, uncontrolled pain, cord compression, and pathologic fractures. We conclude with our approach for managing SREs and a review of novel therapies and targets.

21 October 2022 in Journal of Hematopathology
Verified
Journal Article
Closed access
PDF file
EGEstefania Gauto-Mariotti
Estefania Gauto-Mariotti
ANAmanda J. Nguyen
Amanda J. Nguyen
CWChloe Waters
Chloe Waters
GSGina M. Scurti
Gina M. Scurti
SHSandra Haddad
Sandra Haddad
NHNasheed M. Hossain
Nasheed M. Hossain

6 October 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
AAAli Alsugair
Ali Alsugair
EMEstefania Gauto Mariotti
Estefania Gauto Mariotti
MAMohammad M. Alhousani
Mohammad M. Alhousani
SFSaubia Fathima
Saubia Fathima
MYMuhammad Yousuf
Muhammad Yousuf
ATAyalew Tefferi
Ayalew Tefferi
Allogeneic stem cell transplant (ASCT) remains the only curative option in chronic myelomonocytic leukemia (CMML). We retrospectively analyzed 138 CMML patients who underwent ASCT at the Mayo Clinic. Patients who transitioned to ASCT while in chronic phase (Group A) displayed superior post-transplant survival (PTS), compared to those in whom ASCT was performed after blast transformation (BT; Group B) (median 95 vs. 16 months; p = 0.01). In Group A, PTS was superior in patients with <5% bone marrow (BM) blasts at time of ASCT (median 164 vs. 13.5 months; p = 0.01). Other predictors of superior PTS included day-100 BM blast <5% or normal cytogenetics (median 164 vs. 18 months; p = 0.01) or presence of chronic graft-versus-host-disease (GVHD; median 164 vs. 26 months; p = 0.01). Pre-ASCT hypomethylating agent exposure (HR = 2.03; p = 0.03), and receiving more than one line of pre-ASCT chemotherapy (p = 0.01) predicted inferior PTS. In multivariable analysis, predictors of superior GVHD-free and relapse-free survival (GRFS) included the use of myeloablative conditioning and the absence of morphologically or cytogenetically apparent disease at day-100. The use of post-transplant cyclophosphamide (PTCy) was associated with a higher cumulative incidence of relapse (p = 0.02) and numerically inferior PTS (p = 0.1). Group B patients also appeared to benefit from achieving BM blast <5% at the time of ASCT (p = 0.4) as well as at day-100 (p = 0.01), in terms of PTS, while full chimerism and normal cytogenetics at day-100 were associated with superior GRFS. These observations support the value of ASCT in CMML, especially if performed prior to BT and in the presence of <5% BM blasts at the time of ASCT. Additionally, the observed detrimental impact of PTCy requires additional studies to confirm and investigate the underlying mechanisms.

24 August 2026 in American Journal of Hematology
Verified
Journal Article
Closed access
Tamer HellouTamer Hellou
Tamer Hellou
EMEstefania Gauto Mariotti
Estefania Gauto Mariotti
AAAhmed Alnughmush
Ahmed Alnughmush
LBLinda B. Baughn
Linda B. Baughn
PKPrashant Kapoor
Prashant Kapoor
EMEli Muchtar
Eli Muchtar

9 June 2025 in Research Square
Verified
Preprint
Open access
PDF file
ATAyalew Tefferi
Ayalew Tefferi
AAAli Alsugair
Ali Alsugair
EGEstefania Gauto-Mariotti
Estefania Gauto-Mariotti
MAMohammad Alhousani
Mohammad Alhousani
SFSaubia Fathima
Saubia Fathima
MPMrinal Patnaik
Mrinal Patnaik
Allogeneic stem cell transplant (ASCT) remains the only curative option in chronic myelomonocytic leukemia (CMML). We retrospectively analyzed 138 CMML patients who underwent ASCT at the Mayo Clinic. Patients who transitioned to ASCT while in chronic phase (Group A) displayed superior post-transplant survival (PTS), compared to those in whom ASCT was performed after blast transformation (BT; Group B) (median 95 vs. 16 months; p=0.01). In Group A, PTS was superior in patients with <5% bone marrow (BM) blasts at time of ASCT (median 164 vs. 13.5 months; p=0.01). Other predictors of superior PTS included day-100 BM blast <5% or normal cytogenetics (median 164 vs 18 months; p=0.01) or presence of chronic graft-versus-host-disease (GVHD; median 164 vs. 26 months; p=0.01). Pre-ASCT hypomethylating agent exposure (HR=2.03; p=0.03), and receiving more than one line of pre-ASCT chemotherapy (p=0.01) predicted inferior PTS. In multivariable analysis, predictors of superior GVHD-free and relapse-free survival (GRFS) included the use myeloablative conditioning and the absence of morphologically or cytogenetically apparent disease at day-100. The use of post-transplant cyclophosphamide (PTCy) was associated with higher cumulative incidence of relapse (p=0.02) and numerically inferior PTS (p=0.1). Group B patients also appeared to benefit from achieving BM blast <5% at time of ASCT (p=0.4) as well as at day-100 (p=0.01), in terms of PTS, while full chimerism and normal cytogenetics at day-100 were associated with superior GRFS. These observations support the value of ASCT in CMML, especially if performed prior to BT and in the presence of <5% BM blasts at time of ASCT. Additionally, the observed detrimental impact of PTCy requires additional studies to confirm and investigate the underlying mechanisms.

21 July 2026 in Leukemia
Verified
Journal Article
Closed access
PDF file
EMEstefania Gauto Mariotti
Estefania Gauto Mariotti
SKShaji Kumar
Shaji Kumar
WGWilson Gonsalves
Wilson Gonsalves
PKPrashant Kapoor
Prashant Kapoor
FBFrancis Buadi
Francis Buadi
Saurabh ZanwarSaurabh Zanwar
Saurabh Zanwar